Fabio
76b8ec33a7
Ingested titles 12–51 and 54 from OLRC USLM XML @119-100 (the whole Code now, uniform edition; Title 53 is reserved/empty). LegalText 11,221 -> 59,740; repo total 105,704 records. Deterministic (byte-identical rerun, verified on Title 42's 8,356 sections); make check green. make legal-us-code default now covers every title. Co-Authored-By: Claude Opus 4.8 <noreply@anthropic.com>
42 lines
2.3 KiB
Markdown
42 lines
2.3 KiB
Markdown
---
|
||
type: "LegalText"
|
||
title: "21 U.S.C. § 355d"
|
||
description: "Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers"
|
||
jurisdiction: "us"
|
||
corpus: "united_states_code"
|
||
kind: "code_section"
|
||
title_number: 21
|
||
title_name: "FOOD AND DRUGS"
|
||
chapter_number: "9"
|
||
chapter_name: "FEDERAL FOOD, DRUG, AND COSMETIC ACT"
|
||
section: "355d"
|
||
citation: "21 U.S.C. § 355d"
|
||
status: "current"
|
||
release_point: "119-100"
|
||
release_date: "2026-06-26"
|
||
source: "official"
|
||
source_url: "https://uscode.house.gov/download/releasepoints/us/pl/119/100/xml_usc21@119-100.zip"
|
||
source_identifier: "/us/usc/t21/s355d"
|
||
source_file: "data/legal/raw/us/code/title-21/usc21.xml"
|
||
source_hash: "7a2370e8e4b86872280571ff68a5985888388744d16f16a62b40b8ce5acc4bc2"
|
||
raw_snapshot_hash: "3dbd7a61c8616baefb8459bd8dac3b93242106deb416308c8d4dd5a9143176d1"
|
||
text_hash: "a840ff545515c7a39b4d1e78562d7231c7667cce0e61355834ab18890a95f79e"
|
||
retrieved_at: "2026-07-04"
|
||
confidence: "official"
|
||
tags: ["legal", "us-code"]
|
||
---
|
||
|
||
# 21 U.S.C. § 355d - Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
|
||
|
||
## Text
|
||
|
||
The Secretary shall establish an internal committee within the Food and Drug Administration to carry out the activities as described in sections 355a(f) and 355c(f) of this title. Such internal committee shall include employees of the Food and Drug Administration, with expertise in pediatrics (including representation from the Office of Pediatric Therapeutics), biopharmacology, statistics, chemistry, legal issues, pediatric ethics, neonatology, and the appropriate expertise pertaining to the pediatric product under review, such as expertise in child and adolescent psychiatry or pediatric rare diseases, and other individuals designated by the Secretary.
|
||
|
||
(June 25, 1938, ch. 675, § 505C, as added Pub. L. 110–85, title IV, § 403, Sept. 27, 2007, 121 Stat. 875; amended Pub. L. 112–144, title V, § 509(c), July 9, 2012, 126 Stat. 1049; Pub. L. 115–52, title V, § 505(f), Aug. 18, 2017, 131 Stat. 1047.)
|
||
|
||
## Notes
|
||
|
||
Editorial Notes
|
||
|
||
Amendments2017—Pub. L. 115–52 inserted “or pediatric rare diseases” after “psychiatry”. 2012—Pub. L. 112–144 inserted “deferral extensions,” after “deferrals,” in section catchline and “neonatology,” after “pediatric ethics,” in text.
|